Medical and social research behind cancer prevention.

6-9, 2009, at the Hilton Americas-Houston Hotel in Houston, Texas. This meeting has turned into a major location for presenting cutting-edge research. As the only extensive conference on cancer prevention in the world, it continues to foster essential cross-disciplinary interactions that are crucial to making essential discoveries and translating them into effective preventive strategies, said conference chairperson Ernest Hawk, M.D., M.P.H., vice president for Cancers Prevention and head of the Division of Cancers Prevention and Population Sciences at the University of Texas M., a clinical-stage company developing brand-new therapeutics and molecular diagnostics that target the underlying mechanisms of tumor, the Knight Cancer Institute at Oregon Health & Technology University and The Leukemia & Lymphoma Culture today announced that Aptose has joined the Beat AML collaboration. Defeat AML is normally a groundbreaking analysis initiative that includes industry and academic collaborators led by best researchers within the Knight Cancer Institute in collaboration with The Leukemia & Lymphoma Culture. Its objective is to accelerate advancement of potential therapies for acute myeloid leukemia . Aptose's lead investigational anticancer therapeutic APTO-253 will be profiled extensively against primary cells from a huge selection of AML patient samples collected by Beat AML contributors.

Other entries from category "revitalization":

Random entries